Patents Examined by Pavanaram K Sripada
-
Patent number: 6084093Abstract: The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: ##STR1## wherein R, R', R.sub.1, R'.sub.1, R.sub.2, R'.sub.2, R.sub.3, R'.sub.3, R.sub.4, R'.sub.4, R.sub.5, R'.sub.5, R.sub.6, R'.sub.6, R.sub.7, R'.sub.7, R.sub.8, R'.sub.8, R.sub.9, and R'.sub.9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.Type: GrantFiled: May 16, 1995Date of Patent: July 4, 2000Assignee: G. D. Searle & Co.Inventors: Dennis P. Riley, Randy H. Weiss, William L. Neuman, Anil S. Modak, Patrick J. Lennon, Karl W. Aston
-
Patent number: 6080855Abstract: Compounds of formula (I) or salts thereof: ##STR1## wherein R.sup.1 is hydrogen, methoxy or formamido; R.sup.2 is an acyl group; CO.sub.2 R.sup.3 is a carboxy group or a carboxylate anion, or R.sup.3 is a carboxy protecting group, pharmaceutically acceptable salt-forming group or in vivo hydrolysable ester group; R.sup.4 represents hydrogen or up to four substituents; X is O, S, SO or SO.sub.2 ; Y is O, S, SO or SO.sub.2 ; n is 0 or 1; and m is 1 or 2. The compounds have antibacterial activity. Methods of synthesis of, and pharmaceutical formulations containing, compounds (I) are also described.Type: GrantFiled: January 8, 1999Date of Patent: June 27, 2000Assignee: Pfizer Inc.Inventors: George Burton, Brian Charles Gasson, Stephen Christopher Martin Fell
-
Patent number: 6077952Abstract: A compound of formula (II) or a salt: ##STR1##Type: GrantFiled: June 8, 1999Date of Patent: June 20, 2000Assignee: Pfizer Inc.Inventors: John Hargreaves Bateson, George Burton, Stephen Christopher Martin Fell
-
Patent number: 6077844Abstract: This invention discloses compounds, and pharmaceutically acceptable salts thereof, useful in therapeutically and/or prophylactically treating patients with an illness. Such illnesses include cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. The compounds themselves, methods of making these compounds, and methods of using these compounds are all disclosed.Type: GrantFiled: March 5, 1999Date of Patent: June 20, 2000Assignee: Duquesne University of the Holy GhostInventor: Aleem Gangjee
-
Patent number: 6077861Abstract: Novel compounds of Formula 1 are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels: ##STR1## wherein "Het" is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; R.sup.a, R.sup.b and R.sup.c each are independently selected from hydrogen, halogen, OH, CF.sub.3, NO.sub.2, or ##STR2## provided R.sup.c is not hydrogen; and when R.sup.a and R.sup.b are hydrogen, R.sup.c may be a heterocyclic moiety selected from the group consisting of imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl, and pyridin-2-yl; R.sup.d and R.sup.e each are independently selected from hydrogen, halogen, CF.sub.3, NO.sub.2 or imidazol-1-yl; m, n and p each are independently selected from an integer of O or 1; and R.sup.f and R.sup.g each are independently hydrogen; C.sub.1-4 alkyl; or R.sup.f and R.sup.Type: GrantFiled: November 23, 1998Date of Patent: June 20, 2000Assignee: Bristol-Myers Squibb CompanyInventors: Jeffrey L. Romine, Scott W. Martin, Piyasena Hewawasam, Nicholas A. Meanwell, Valentin K. Gribkoff, John E. Starrett, Jr.
-
Patent number: 6072081Abstract: An optically active bisoxazoline compound of the formula [I]: ##STR1## wherein R.sub.1 represents alkyl group, cycloalkyl group, aralkyl group, phenyl group which may be substituted or alkoxy group and two geminal alkyl groups may be joined together to form a cyclic structure;R.sub.2 represents alkyl group, cycloalkyl group, aralkyl group, phenyl group which may be substituted;R.sub.3 represents hydrogen atom, (C2-C4)alkyl group or cycloalkyl group; andthe asterisk * represents an asymmetric carbon atom.Type: GrantFiled: August 4, 1998Date of Patent: June 6, 2000Assignee: Sumitomo Chemical Company, LimitedInventors: Makoto Itagaki, Gohfu Suzukamo
-
Patent number: 6071925Abstract: The present invention relates to compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each independently hydrogen, lower alkyl, lower alkoxy or halogen;R.sup.3 is phenyl, which is unsubstituted or substituted by lower alkyl, CF.sub.3, lower alkoxy or halogen;R.sup.4 is hydrogen, lower alkyl, lower alkenyl, --C(O)-lower alkyl, --C(O)-phenyl, lower alkyl-C(O)-phenyl, lower alkylene-C(O)O-lower alkyl, lower alkantriyl-di-C(O)O-lower alkyl, hydroxy-lower alkyl, lower alkyl-O-lower alkyl, lower alkyl-CH(OH)CF.sub.3, phenyl or benzyl,R.sup.5 and R.sup.6 are each independently hydrogen, phenyl, lower alkyl or di-lower alkyl or R.sup.5 and R.sup.6 together with the carbon atoms to which they are bound form a phenyl ring, orR.sup.5 and one of R.sup.1 or R.sup.Type: GrantFiled: January 20, 1998Date of Patent: June 6, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Geo Adam, Andrea Cesura, Guido Galley, Fran.cedilla.ois Jenck, Frederick Monsma, Jr., Stephan Rover, Jurgen Wichmann
-
Patent number: 6069244Abstract: A phthalocyanine compound possessing an excellent ability to absorb near infrared ray, exhibiting excellent compatibility with resin, and excelling in such special qualities as heat resistance, light resistance, and resistance to weather conditions is provided. This phthalocyanine compound is represented by the following general formula (1) ##STR1## wherein Z.sub.2, Z.sub.3, Z.sub.6, Z.sub.7, Z.sub.10, Z.sub.11, Z.sub.14, and Z.sub.15 are independently SR.sup.1, OR.sup.2, or a fluorine atom, and at least one of them is for SR.sup.1 or OR.sup.2, Z.sub.1, Z.sub.4, Z.sub.5, Z.sub.8, Z.sub.9, Z.sub.12, Z.sub.13, and Z.sub.16 independently stand for NHR.sup.3, SR.sup.1, OR.sup.2, or a fluorine atom and at least one of them is NHR.sup.3, at least one of Z.sub.1 to Z.sub.16 is a fluorine atom or OR.sup.2, R.sup.1, R.sup.2, and R.sup.Type: GrantFiled: February 3, 1999Date of Patent: May 30, 2000Assignee: Nippon Shokubai Co., Ltd.Inventors: Kiyoshi Masuda, Osamu Kaieda
-
Patent number: 6066635Abstract: The present invention provides a compound having the structure ##STR1## wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are independently selected from H, alkyl, aminoalkyl, perfluoroalkyl, orpharmaceutically acceptable salts thereof, useful for treating cancer.Type: GrantFiled: March 23, 1999Date of Patent: May 23, 2000Assignee: University of California, San DiegoInventors: William Fenical, Paul R. Jensen, Xing C. Cheng
-
Patent number: 6066646Abstract: A compound of formula (I):P--R.sup.2 --Q (I)where each of P and Q is, independently, a group of formula (B): ##STR1## wherein J is a bidentate group of formula --CH.sub.2 --X--CH.sub.2 -- (wherein X is methylene, sulfur or oxygen), X'C.dbd.CY or X'WC--CYZ (wherein X', W, Y and Z are independently hydrogen, hydroxy, acyloxy, alkoxy, alkylsilyloxy or halogen); R.sup.1 is an optionally substituted phenyl or 5-or 6-membered heterocyclic ring system containing from 1 to 3 heteroatoms individually selected from nitrogen, oxygen and sulfur atoms, and at least one unsaturation (double bond) between adjacent atoms in the ring, said heterocyclic ring being optionally fused to a benzene ring, wherein the substutuents, if present, are selected from halogen atoms, cyano, alkyl, alkenyl, alkynyl, alkoxy, haloalkyl, haloalkenyl, alkylthio and alkyl amino groups, any of which groups contain up to six carbon atoms; R.sup.Type: GrantFiled: February 12, 1999Date of Patent: May 23, 2000Assignee: Zeneca LimitedInventors: Nigel Douglas Bishop, Christopher John Urch, Terence Lewis, Raymond Leo Sunley, Roger Salmon, Christopher Richard Ayles Godfrey
-
Patent number: 6066729Abstract: A photothermal conversion material showing high sensitivity to the light of a semiconductor laser having an emission frequency band of 750 nm.about.900 nm with a high photothermal conversion efficiency and a planographic original plate fabricated by using the transducer are provided. This photothermal conversion material comprises a phthalocyanine compound of the following general formula (I) ##STR1## wherein R.sub.1 .about.R.sub.8 each represents alkyl or alkoxyalkyl; X.sub.1 .about.X.sub.8 each represents sulfur or NR.sub.9, where R.sub.9 is hydrogen or alkyl.Type: GrantFiled: November 17, 1998Date of Patent: May 23, 2000Assignee: Yamamoto Chemicals, IncInventors: Shigeo Fujita, Jun-ichi Taniguchi, Hiroshi Terao, Yojiro Kumagae
-
Patent number: 6066628Abstract: The present disclosure provides novel non-iron metalloporphyrins, especially those porphyrin complexes containing gallium or indium as the metal ion, and antibacterial compositions comprising artificial metalloporphyrins (such as protoporphyrin IX) completed with a metal ion selected from metal ions including, but not limited to, gadolinium, ruthenium copper, gallium, indium and manganese, and methods for inhibiting or killing bacteria and other microorganisms and for treating infections caused by microorganisms using the artificial metalloporphyrin of the present invention.Type: GrantFiled: January 9, 1998Date of Patent: May 23, 2000Assignee: Emory UniversityInventors: Igor Stojiljkovic, Gordon G. Churchward
-
Patent number: 6063777Abstract: The present invention provides an iminochlorin aspartic acid derivative represented by the following formula (I): ##STR1## Wherein Asp represents an aspartic acid residue, or a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a photosensitizer for photophysico-chemical diagnosis and therapy of cancer, because it has a high accumulability to cancerous cells, reactivity to external energy and a cancerous cell destroying effect which is effective even against cancers developing in deep site, while it is rapidly excreted from normal cells and therefore causes no damage thereto.Type: GrantFiled: June 15, 1999Date of Patent: May 16, 2000Assignees: Wyeth Lederle Japan, Ltd., Photochemical Co., Ltd.Inventors: Muneo Hikida, Masahiko Mori, Isao Sakata, Susumu Nakajima, Hiroyuki Takata
-
Patent number: 6063917Abstract: A process for the production of a compound of formula ##STR1## wherein R.sup.a denotes hydrogen or silyl;R.sup.b denotes a group of formula --OR.sup.e, whereinR.sup.e denotes hydrogen or alkyl; andR.sup.c and R.sup.d together denote a bond;in free form or in salt form,which process comprises the step of spitting, in the presence of ozone, the double bond in position 3 of the ring structure of a compound of formula III ##STR2## wherein R.sub.2 and R.sub.3 are the same or different and independently of each other denote hydrogen or an organic group, and X.sup.- denotes the anion of an inorganic or organic acid and optionally silylating the amine group in position 7 of the ring system.Type: GrantFiled: September 30, 1998Date of Patent: May 16, 2000Assignee: Biochemie Gesellschaft m.b.H.Inventors: Gerd Ascher, Johannes Ludescher, Hubert Sturm, Josef Wieser
-
Patent number: 6060598Abstract: Fluorescence immunoassays methods are provided which use fluorescent dyes which are free of aggregation and serum binding. Such immunoassay methods are thus, particularly useful for the assay of biological fluids, such as serum, plasma, whole blood and urine.Type: GrantFiled: June 13, 1997Date of Patent: May 9, 2000Assignee: Hyperion, Inc.Inventors: Robert Francis Devlin, Walter Beach Dandliker, Peter Olaf Gustaf Arrhenius
-
Patent number: 6054449Abstract: A broad class of photosensitive compounds having enhanced in vivo target tissue selectivity and versatility in photodynamic therapy. Many furocoumarin compounds, such as psoralens, exhibit cytostatic activity when photoactivated but exhibit little in vivo specificity for selectively accumulating in any particular target tissue such as atheromatous plaques. Reactive Oxygen Producing Photosensitizers ("ROPPs") are photoactivatable compounds having an affinity for hyperproliferating cells (such as atheromatous plaque cells), which when photoactivated, produce cytotoxic reaction products. The photoactivity of a ROPP, such as a porphyrin, may be reduced by metalating the porphyrin while the selective affinity of the metalized ROPP for hyperproliferating tissue remains substantially unchanged.Type: GrantFiled: February 14, 1997Date of Patent: April 25, 2000Assignee: Miravant Pharmaceuticals, Inc.Inventors: Byron Robinson, Alan R. Morgan, Hugh L. Narciso, Jr.
-
Patent number: 6054448Abstract: Compounds of the formula ##STR1## in which R.sup.1 is Y or Y--C.sub.1-6 alkyl, where Y is carboxy, tetrazolyl, --SO.sub.2 H, --SO.sub.3 H, --OSO.sub.3 H, --CONHOH, or --P(OH)OR', --PO(OH)OR', --OP(OH)OR' or --OPO(OH)OR' where R' is hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl or optionally substituted phenyl-C.sub.1-6 alkyl,and R.sup.2, R.sup.3, R.sup.4, X and Z are as defined in the specification, possess affinity for metabotropic glutamate receptors and are useful in the treatment of disorders of the central nervous system.Type: GrantFiled: October 17, 1997Date of Patent: April 25, 2000Assignee: Eli Lilly and Company LimitedInventors: Barry Peter Clark, John Richard Harris
-
Patent number: 6054580Abstract: A robust compound is provided having the formula: ##STR1## wherein Y.sub.1, Y.sub.2, Y.sub.3 and Y.sub.4 are oxidation resistant groups which are the same or different and which form 5- or 6-membered rings with a metal, M, when bound to D. D is a metal complexing donor atom, O or N. Each X is a position for addition of a substituent and, when D is N, each position is (i) not occupied such that a double bond is formed between D and an atom adjacent to D, or (ii) is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, alkoxy, phenoxy, halogen, halogenated alkyl, halogenated aryl, halogenated alkenyl, halogenated alkynyl, perhaloalkyl, perhaloaryl, a substituted or unsubstituted cycloalkyl ring, a substituted or unsubstituted cycloalkenyl ring, a substituted or unsubstituted saturated heterocyclic ring, a substituted or unsubstituted unsaturated heterocyclic ring, and at least one X is hydrogen, and when D is O, the position is not occupied.Type: GrantFiled: June 12, 1998Date of Patent: April 25, 2000Assignee: Carnegie Mellon UniversityInventors: Terrence J. Collins, Scott W. Gordon-Wylie, Colin P. Horwitz
-
Patent number: 6054584Abstract: A process for extracting morphine from opium is described. In the process, opium is extracted with a basic alcoholic solution. The basic alcoholic solution is filtered and the alcohol removed from the filtrate to leave a residue. The residue is then extracted with a basic aqueous solution having a pH of at least 11. The basic aqueous solution may be filtered to remove any solid matter remaining after the aqueous extraction step, and then be stirred with a sufficient amount of a salt to avoid emulsion formation. The basic aqueous solution or filtrate is then extracted with benzene or toluene. Next, adjusting the pH of the basic aqueous filtrate to pH 8.5 to 9.5 allows the morphine to precipitate and be recovered.Type: GrantFiled: November 19, 1996Date of Patent: April 25, 2000Assignee: The Board of Regents of the University and Community College System of NevedaInventors: Junning Ma, Robert C. Corcoran
-
Patent number: 6054604Abstract: The present invention relates to new processes for preparing norbenzomorphan, the central intermediate step in the preparation of pharmaceutically useful benzomorphan derivatives of general formula 1 ##STR1## especially (-)-(1R,5S,2"R)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9-trimethyl-6,7-benzomo rphan or [(-)-(2R,6S,2'R)-3-(2-methoxypropyl)-6,11,11-trimethyl-1,2,3,4,5,6-hexahyd ro-2,6-methano-benzo[.alpha.]oxacin-9-ol] (BIII 277).Type: GrantFiled: February 24, 1999Date of Patent: April 25, 2000Assignee: Boehringer Ingelheim KGInventors: Matthias Grauert, Herbert Merz, Hanfried Baltes